Sampling Human
Private Company
Total funding raised: $4.2M
Overview
Sampling Human is a private, early-stage diagnostics company pioneering single-cell analysis technologies. While the company's specific platform and pipeline are not detailed on its public homepage, its mission statement and association with high-profile scientific advisors suggest a focus on translating single-cell research into clinical tools. The company is pre-revenue and in a pre-clinical or early development stage, building its scientific foundation and leadership team.
Technology Platform
Focused on single-cell precision analysis, likely for diagnostic applications. Specific platform details (e.g., sequencing, imaging, microfluidics) are not disclosed, but the mission and advisor expertise suggest a platform to analyze individual cells from liquid or tissue biopsies for clinical decision-making.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Sampling Human competes in the crowded and rapidly evolving single-cell analysis and liquid biopsy markets. Key competitors include platform technology companies like 10x Genomics and Mission Bio, as well as diagnostic firms like Guardant Health, Freenome, and Epic Sciences. Differentiation will require demonstrating superior clinical utility, workflow advantages, or unique biological insights.